213 related articles for article (PubMed ID: 28400260)
1. Prevention of the adverse effects of olanzapine on lipid metabolism with the antiepileptic zonisamide.
Stefanidis A; Watt MJ; Cowley MA; Oldfield BJ
Neuropharmacology; 2017 Sep; 123():55-66. PubMed ID: 28400260
[TBL] [Abstract][Full Text] [Related]
2. Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects.
Coccurello R; Caprioli A; Ghirardi O; Conti R; Ciani B; Daniele S; Bartolomucci A; Moles A
Psychopharmacology (Berl); 2006 Jul; 186(4):561-71. PubMed ID: 16758241
[TBL] [Abstract][Full Text] [Related]
3. Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis.
Albaugh VL; Judson JG; She P; Lang CH; Maresca KP; Joyal JL; Lynch CJ
Mol Psychiatry; 2011 May; 16(5):569-81. PubMed ID: 20308992
[TBL] [Abstract][Full Text] [Related]
4. The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats.
Fell MJ; Anjum N; Dickinson K; Marshall KM; Peltola LM; Vickers S; Cheetham S; Neill JC
Psychopharmacology (Berl); 2007 Oct; 194(2):221-31. PubMed ID: 17581744
[TBL] [Abstract][Full Text] [Related]
5. The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance.
Lykkegaard K; Larsen PJ; Vrang N; Bock C; Bock T; Knudsen LB
Schizophr Res; 2008 Aug; 103(1-3):94-103. PubMed ID: 18579346
[TBL] [Abstract][Full Text] [Related]
6. Chronic treatment with olanzapine increases adiposity by changing fuel substrate and causes desensitization of the acute metabolic side effects.
Girault EM; Guigas B; Alkemade A; Foppen E; Ackermans MT; la Fleur SE; Fliers E; Kalsbeek A
Naunyn Schmiedebergs Arch Pharmacol; 2014 Feb; 387(2):185-95. PubMed ID: 24190543
[TBL] [Abstract][Full Text] [Related]
7. The role of thermogenesis in antipsychotic drug-induced weight gain.
Stefanidis A; Verty AN; Allen AM; Owens NC; Cowley MA; Oldfield BJ
Obesity (Silver Spring); 2009 Jan; 17(1):16-24. PubMed ID: 19107124
[TBL] [Abstract][Full Text] [Related]
8. Chronic olanzapine administration in rats: effect of route of administration on weight, food intake and body composition.
Mann S; Chintoh A; Giacca A; Fletcher P; Nobrega J; Hahn M; Remington G
Pharmacol Biochem Behav; 2013 Feb; 103(4):717-22. PubMed ID: 23234835
[TBL] [Abstract][Full Text] [Related]
9. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis.
Graham KA; Perkins DO; Edwards LJ; Barrier RC; Lieberman JA; Harp JB
Am J Psychiatry; 2005 Jan; 162(1):118-23. PubMed ID: 15625209
[TBL] [Abstract][Full Text] [Related]
10. Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats.
Wallingford NM; Sinnayah P; Bymaster FP; Gadde KM; Krishnan RK; McKinney AA; Landbloom RP; Tollefson GD; Cowley MA
Neuropsychopharmacology; 2008 Nov; 33(12):2922-33. PubMed ID: 18322467
[TBL] [Abstract][Full Text] [Related]
11. A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain.
McElroy SL; Winstanley E; Mori N; Martens B; McCoy J; Moeller D; Guerdjikova AI; Keck PE
J Clin Psychopharmacol; 2012 Apr; 32(2):165-72. PubMed ID: 22367654
[TBL] [Abstract][Full Text] [Related]
12. Effects of olanzapine and haloperidol on the metabolic status of healthy men.
Vidarsdottir S; de Leeuw van Weenen JE; Frölich M; Roelfsema F; Romijn JA; Pijl H
J Clin Endocrinol Metab; 2010 Jan; 95(1):118-25. PubMed ID: 19906788
[TBL] [Abstract][Full Text] [Related]
13. Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents.
Albaugh VL; Henry CR; Bello NT; Hajnal A; Lynch SL; Halle B; Lynch CJ
Obesity (Silver Spring); 2006 Jan; 14(1):36-51. PubMed ID: 16493121
[TBL] [Abstract][Full Text] [Related]
14. Olanzapine-depot administration induces time-dependent changes in adipose tissue endocrine function in rats.
Horska K; Ruda-Kucerova J; Babinska Z; Karpisek M; Demlova R; Opatrilova R; Suchy P; Kotolova H
Psychoneuroendocrinology; 2016 Nov; 73():177-185. PubMed ID: 27504985
[TBL] [Abstract][Full Text] [Related]
15. Metabolic side effects induced by olanzapine treatment are neutralized by CB1 receptor antagonist compounds co-administration in female rats.
Lazzari P; Serra V; Marcello S; Pira M; Mastinu A
Eur Neuropsychopharmacol; 2017 Jul; 27(7):667-678. PubMed ID: 28377074
[TBL] [Abstract][Full Text] [Related]
16. Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain.
Cooper GD; Harrold JA; Halford JC; Goudie AJ
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):428-36. PubMed ID: 17933447
[TBL] [Abstract][Full Text] [Related]
17. Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats.
Skrede S; Fernø J; Vázquez MJ; Fjær S; Pavlin T; Lunder N; Vidal-Puig A; Diéguez C; Berge RK; López M; Steen VM
Int J Neuropsychopharmacol; 2012 Mar; 15(2):163-79. PubMed ID: 21854679
[TBL] [Abstract][Full Text] [Related]
18. Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration.
Minet-Ringuet J; Even PC; Goubern M; Tomé D; de Beaurepaire R
Appetite; 2006 May; 46(3):254-62. PubMed ID: 16551485
[TBL] [Abstract][Full Text] [Related]
19. Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.
Raskind MA; Burke BL; Crites NJ; Tapp AM; Rasmussen DD
Neuropsychopharmacology; 2007 Feb; 32(2):284-8. PubMed ID: 16710316
[TBL] [Abstract][Full Text] [Related]
20. Estrogen replacement reverses olanzapine-induced weight gain and hepatic insulin resistance in ovariectomized diabetic rats.
Park S; Hong SM; Ahn IL; Kim DS; Kim SH
Neuropsychobiology; 2010; 61(3):148-61. PubMed ID: 20173353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
